Role of Resection of the Primary Pancreatic Neuroendocrine Tumor in the Multidisciplinary Treatment of Patients with Unresectable Synchronous Liver Metastases: A Case Series
Abstract
Context Liver metastases have often existed in patients who have pancreatic neuroendocrine tumors (pNETs) at the time of diagnosis. In the management of patients of pNETs with unresectable liver metastases, the clinical efficacy of surgery to primary pancreatic tumor has been controversial. We presented four patients who were treated with resection of primary pancreatic tumor, trans-arterial hepatic treatment and systemic therapies. We reviewed literatures and discussed about role of resection of primary pancreatic tumor in the multidisciplinary treatment. Methods We retrieved medical records of patients who had been histopathologically diagnosed as pNETs at our institution between April 2000 and March 2006, and found 4 patients who had pNETs with unresectable synchronous liver metastases and no extrahepatic metastases. All patients received resection of primary tumor. Patients’ demographics, pathology, treatment, short- and long-term outcome were examined. Results In short-term outcome analysis, delayed gastric emptying was developed in one patient who received pancreaticoduodenectomy. There were no other significant postoperative complications. As for long-term outcome, two patients who received distal pancreatectomy, sequential trans-arterial treatments and systemic therapies could survive for long time relatively. They died 92 and 73 months after the first treatment, respectively. One patient who received distal pancreatectomy and trans-arterial treatment died from unrelated disease 14 months after the first treatment. Another patient who received preoperative trans-arterial treatments and pancreaticoduodenectomy rejected postoperative trans-arterial treatment, was treated with systemic therapies and died 37 months after the initial treatment. Conclusions Resection of primary pNETs would be considered as an optional treatment for the selected patients who had unresectable synchronous liver metastases in the process of the multidisciplinary approach.
Image: Microscopic images of three patients of pNETs.
Downloads
References
Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007; 14(12): 3492-500. [PMID 17896148]
Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol. 2012; 19(9):2932-6. [PMID 22350605]
Bosman FT, Carneiro Fatima, Hruban RH, Theise ND (Eds): WHO classification of tumours of the digestive system. (4th edition). IARC Press: Lyon 2010:322-6.
Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998; 187(1):88-92. [PMID 9660030]
Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190(4): 432-445. [PMID 10757381]
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97(4): 934-9. [PMID 12569593]
Oh TG, Chung MJ, Park JY, Bang SM, Park SW, Chung JB, et al. Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience. Yonsei Med J. 2012; 53(5):944-51. [PMID 22869477]
Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12(4):1083-92. [PMID 16322345]
Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumors of the duodenopancreatic area. Gut 1998; 43(3):422-7. [PMID 9863490]
Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005; 16(11):1806-10. [PMID 16085691]
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Version 1.2012 Neuroendocrine tumors of the pancreas. http://www.nccn.org/professionals/ physician_gls/pdf/neuroendocrine.pdf
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012; 95(2):157-76. [PMID 22262022]
Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012; 95(2):120-34. [PMID 22261872]
Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010; 39(6):735-52. [PMID 20664472]
Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008; 87(1):8-19. [PMID 18097129]
Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010; 39(6):753-66. [PMID 20664473]
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. [PMID 21306238]
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. [PMID 21306237]
Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006; 95(9):1148-54. [PMID 17031397]
Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scitigraphy. Mod Pathol 2007; 20(11):1172-82. [PMID 17873898]
Wente MN, Bassi C, Devenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayd gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007; 142(5):761-8. [PMID 17981197]
Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45(2):234-43. [PMID 20058030]
Eriksson B, Oberg K: Neuroendocrine tumours of the pancreas. Br J Surg 2000; 87(2): 129-31. [PMID 10671915]
Ito T, Tanaka M, Sasano H, Osamura YR, Sasaki I, Kimura W, et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol. 2007; 42(6):497-500. [PMID 17671766]
Zerbi A, Falconi M, Rindi G, Delle Fave G, Tomassetti P, Pasquali C, et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol. 2010; 105(6):1421-9. [PMID:20087335]
Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009; 115(4):741-51. [PMID 19130464]
Tsuchikawa T, Hirano S, Tanaka E, Kato K, Matsumoto J, Nakayama T, et al. Surgical strategy for liver metastases of neuroendocrine tumors. Hepatogastroenterology. 2012; 59(115):921-3. [PMID 22024223]
Saxena A, Chua TC, Zhao J, Morris DL. Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery. J Surg Oncol. 2012; 105(4):342-50. [PMID 22006355]
Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000; 190(4):432-45. [PMID 10757381]
Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in contemporary series of 163 patients. Surgery. 2001; 130(6):1078-85. [PMID 11742342]
Metz DC, Benjamin SB. Islet cell carcinoma of the pancreas presenting as bleeding from isolated gastric varices. Report of a case and review of the literature. Dig Dis Sci. 1991; 36(2):241-4. [PMID 1846333]
Yamaguchi T, Takahashi H, Kagawa R, Takeda R, Sakata S, Yamamoto M, et al. Nonfunctioning pancreatic endocrine tumor presenting with hemorrhage from isolated gastric varices. Am Surg. 2005; 71(12):1027-30. [PMID 16447473]
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005; 104(8):1590-602. [PMID 16134179]
Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Fave GD, Falconi M. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology. 2011; 93(4):223-9. [PMID 21358176]
Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007; 31(12):2392-7. [PMID 17960455]
Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221:721-31. [PMID 7794076]
Gordon TA, Burleyson GP, Tielsch JM, Cameron JL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995; 221:43-9. [PMID 7826160]
Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996; 223: 506-11. [PMID 8651741]
Chen C, Tsang YM, Hsueh PR, Huang GT, Yang PM, Sheu JC, et al. Bacterial infections associated with hepatic arteriography and transarterial embolization for hepatocellular carcinoma: a prospective study. Clin Infect Dis. 1999; 29(1):161-6. [PMID 10433580]
Ishikawa O, Ohigashi H, Yasuda T, Shibata T, Sasaki Y, Kameyama M, et al. Transarterial chemoembolization in metastatic liver tumor after curative resection of pancreatic cancer. (Article in Japanese) Gan To Kagaku Ryoho. 1988; 15(8 Pt 2):2505-9. [PMID 2843113]
Oberstein PE, Saif MW. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol. 2012; 6:41-51. [PMID 22253554]
Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, et al. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. 2012; 7(2):117-25. [PMID 22661319]
Oberstein PE, Remotti H, Saif MW, Libutti SK. Pancreatic neuroendocrine tumors: entering a new era. JOP. 2012; 13(2):169-73. [PMID 22406593]
Oberstein PE, Saif MW. Update on novel therapies for pancreatic neuroendocrine tumors. JOP. 2012; 13(4):372-5. [PMID 22797392]
Copyright (c) 2014 Naoko Iwahashi Kondo, Yasuharu Ikeda, Shin-ichiro Maehara, Rie Sugimoto, Ken-ichi Nishiyama, Yoshihisa Sakaguchi
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.